EANM Young Authors Award

EANM is offering an award to young authors of very good quality abstracts accepted for presentation at the EANM annual congress. The purpose of this award is to encourage young and talented nuclear medicine investigators to submit their results to the annual EANM congress and to have the financial aid to attend the meeting and present their work.

 

Who can apply?

  • The applicant must be aged 38 years or less.
  • The applicant must be the first author of the presented work.
  • The applicant must be a junior or ordinary member of EANM.
  • At least one of the authors of the paper must attend the congress.

The Award

  • Lump-sum subsidy of € 1.000,- for the first author.
  • Free registration for EANM’21.

There are up to 3 grants per annual congress.

 

Application and Procedure:

Application:
The applicant must indicate during the abstract submission process (by ticking the relevant box) that he/she would like to apply for this award. Once the applicant is shortlisted, the presenting author will be requested to scan and email a copy of passport or birth certificate as a proof of age.
The deadline for the application will be the same as for the submission of abstracts for the EANM Annual Congress.

Selection Procedure:
Once the submission of abstracts is closed, the review process will starts. After the review process, approx. the best rated 15 papers who applied for the  “EANM Young Authors Award” are shortlisted. Those abstracts will be sent (anonymized) to the EANM Scientific Programme Committee. The 3 best-rated papers will be awarded the “EANM Young Authors Award”.

 

 

In 2020 we congratulated:

Winner Pres.No.   Abstract Title   Author Block
           
Bastiaan Privé   OP-982 [177Lu]Lu-PSMA-617 in low-volume metastatic hormone sensitive prostate cancer: a prospective pilot study B. Prive1, S. M. B. Peters1, C. H. J. Muselaers1, P. Zamecnik1, M. J. R. Janssen1, T. W. J. Scheenen1, M. W. Konijnenberg1, J. Verzijlbergen1, W. R. Gerritsen1, N. Mehra1, D. M. Somford2, J. A. Van Basten2, I. M. Van Oort1, J. Sedelaar1, J. O. Barentsz1, S. Heskamp1, M. Gotthardt1, J. Witjes1, J. Nagarajah1;
1Radboudumc, Nijmegen, NETHERLANDS, 2Canisius Wilhelmina Hospital, Nijmegen, NETHERLANDS.
   
Elin Pauwels   OP-270 [18F]AlF-NOTA-octreotide PET imaging: Pharmacokinetics, biodistribution, and head-to-head comparison with [68Ga]Ga-DOTATATE in neuroendocrine tumour patients E. Pauwels1, F. Cleeren2, T. Tshibangu2, M. Koole1, K. Serdons1, J. Dekervel3, E. Van Cutsem3, C. Verslype3, K. Van Laere1, G. Bormans2, C. M. Deroose1;
1Nuclear Medicine, University Hospitals Leuven; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM, 2Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, BELGIUM, 3Digestive Oncology, University Hospitals Leuven, Leuven, BELGIUM.
   
Edward O’Neill   OP-111 Ratiometric relationship between γH2AX imaging and Lutetium-177 is predictive of survival following radionuclide therapy in vivo E. O’Neill, G. M. Dias, B. Cornelissen;
University of Oxford, Oxford, UNITED KINGDOM.